Center for Innovation and Stimulation of Medicines Development

Leuven, Belgium

Center for Innovation and Stimulation of Medicines Development

Leuven, Belgium
SEARCH FILTERS
Time filter
Source Type

Kundarapu M.,Rega Institute for Medical Research | Marchand D.,Center for Innovation and Stimulation of Medicines Development | Dumbre S.G.,Rega Institute for Medical Research | Herdewijn P.,Rega Institute for Medical Research
Tetrahedron Letters | Year: 2011

A series of 2′ functionalized acyclic nucleoside phosphonate derivatives of 1-[3′-(phosphonomethoxy)propyl]uracil (1-4) have been synthesized together with the 1′ and 2′-ethynyl derivatives of 9/1-[2′-(phosphonomethoxy)ethyl]adenine/thymine (5-7). Key intermediates leading to the latter series are (±)-[2-{diethyl(phosphonomethoxy)}-1- hydroxy]-but-3-yne (25) and (±)-diisopropyl{[2-hydroxy-4-(trimethylsilyl) but-3-yn-1-yl]oxy}methylphosphonate (30). Compounds 25 and 30 are easily obtained starting from (±)-solketal. © 2011 Elsevier Ltd. All rights reserved.


Christ F.,Catholic University of Leuven | Voet A.,Laboratory for Biomolecular Modelling | Marchand A.,Center for Innovation and Stimulation of Medicines Development | Nicolet S.,Catholic University of Leuven | And 10 more authors.
Nature Chemical Biology | Year: 2010

Lens epitheliumĝ€"derived growth factor (LEDGF/p75) is a cellular cofactor of HIV-1 integrase that promotes viral integration by tethering the preintegration complex to the chromatin. By virtue of its crucial role in the early steps of HIV replication, the interaction between LEDGF/p75 and integrase represents an attractive target for antiviral therapy. We have rationally designed a series of 2-(quinolin-3-yl)acetic acid derivatives (LEDGINs) that act as potent inhibitors of the LEDGF/p75-integrase interaction and HIV-1 replication at submicromolar concentration by blocking the integration step. A 1.84-Å... resolution crystal structure corroborates the binding of the inhibitor in the LEDGF/p75-binding pocket of integrase. Together with the lack of cross-resistance with two clinical integrase inhibitors, these findings define the 2-(quinolin-3-yl)acetic acid derivatives as the first genuine allosteric HIV-1 integrase inhibitors. Our work demonstrates the feasibility of rational design of small molecules inhibiting the protein-protein interaction between a viral protein and a cellular host factor.

Loading Center for Innovation and Stimulation of Medicines Development collaborators
Loading Center for Innovation and Stimulation of Medicines Development collaborators